Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This paper discusses prostate cancer diagnosis and treatment controversies and advocates for individualized approaches, reporting no new findings.

This review explores how androgens and growth hormone influence the development of terminal hairs and sebaceous glands, attributing variability in hirsutism and acne to differing genetic sensitivities to androgens, but reports no new experimental data.

This study suggests that a combination of topical minoxidil with oral finasteride and dutasteride may promote new hair growth in androgenetic alopecia, with minor safety concerns reported.

This article outlines the author's personal strategies for managing dermatological toxicities, such as acneiform rash and dry skin, associated with EGFR inhibitor therapy; it does not present new research findings.

This review discusses the various treatment options for male and female pattern hair loss and provides no new clinical results; the authors outline the most effective strategies based on existing evidence.

This review examines recent approvals and emerging treatments for androgenetic alopecia, discussing newly approved drugs like Propecia and Rogaine Extra Strength 5%, but without presenting new clinical results.

Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.

This review discusses the etio-pathogenetic factors in benign prostatic hyperplasia and their role in the development of lower urinary tract symptoms but reports no new research findings.

This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.

This study found low- to very low-quality evidence suggesting that several pharmacological treatments, including alpha blockers and antibiotics, may reduce prostatitis symptoms without significantly increasing adverse events in the short term, although more rigorous trials are needed.

This review summarizes current and emerging treatments for common hair loss conditions, highlighting good evidence for androgenetic alopecia but noting the lack of long-term data for alopecia areata and cicatricial alopecias.

This article reviews the pathophysiology, diagnosis, and treatment of androgenic alopecia but reports no new clinical findings.

This study discusses the physiopathogeny, clinical manifestations, and treatment objectives of androgenetic alopecia without reporting new clinical findings.

This source provides a comprehensive reference on recent advancements and innovative approaches in the diagnosis and treatment of common dermatological conditions, highlighting significant updates for clinical practice in dermatology.

This article discusses vaccination coverage for BCG, Polio, and Hepatitis B in Juiz de Fora using SUS data and reports no new results; the authors aim to hypothesize reasons for coverage variation.

This source provides an overview of the dietary recommendations for macronutrient intake and the benefits of plant-based diets, including meeting essential amino acid needs through combining plant proteins and the advantages of consuming complex carbohydrates and adequate fiber for health.

This review discusses the dual role of the TMPRSS2 gene in coronaviral lung infection and prostate cancer, cautioning against TMPRSS2 inhibitors for early prostate cancer due to potential pro-inflammatory effects.

This study highlights that improved diagnostic techniques for prostate cancer could decrease the number of men needing diagnosis and treatment to save one life and identifies avoidable risk factors, such as smoking, diet, and occupation, that may influence prostate cancer risk.

This study found that utilizing a clinical pharmacist in perioperative urological services reduced surgical cancellations and resident overtime while improving service efficiency and financial sustainability.

This abstract provides no results, as it only notes Sharon Keene's professional role and describes a non-blood test for AGA genetics.

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.

This study found that serum PSA levels are higher in hirsute women and can be significantly reduced by antiandrogen treatment, suggesting PSA as a marker of androgen action in females.

This study found that women with PCOS have higher total PSA levels than controls, and the total PSA level correlates positively with testosterone and free androgen index.

In this study, higher urethral prostate-specific antigen (urPSA) levels in men after radical prostatectomy were associated with higher androgenic alopecia scores and higher postoperative PSA.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study found that finasteride and its combination with terazosin significantly reduced PSA levels in patients with benign prostatic hyperplasia, whereas terazosin alone showed no clinically significant effect.

In this study, the combination of Serenoa repens extract with Phenolmicin P3 and Bosexil suppositories significantly improved lower urinary tract symptoms and decreased PSA levels in patients with benign prostatic obstruction-related symptoms.

This study found that weekly low-dose bicalutamide was safe and appeared to be associated with high-grade PIN remission and favorable PSA modulation in subjects with persistently elevated PSA but negative biopsy.

This study found that finasteride does not increase the risk of high-grade prostate cancer but instead improves the prostate-specific antigen test's sensitivity to detect such cancers.